Conference Coverage

FDA’s Project Optimus aims to transform early cancer research


 

AT SITC 2023

Q: How will all this affect drug development?

Dr. Yeung: Drugs may become more expensive because much more testing will happen during clinical trials.

Q: Could this reduce the number of investigational drugs?

Dr. Yeung: Hopefully not, but this is huge endeavor for smaller companies that are strapped for funding.

Q: What do you think the future holds?

Dr. Yeung: Ultimately, this is a good thing because if everything works out, we’ll have fewer toxic side effects. But we’re going to have to go through a period of growing pains.

Pages

Recommended Reading

FDA approves dasatinib for kids with Ph+ ALL
MDedge Hematology and Oncology
EC approves split dosing regimen for daratumumab
MDedge Hematology and Oncology
FDA approves first treatment for BPDCN
MDedge Hematology and Oncology
FDA approves ravulizumab for PNH
MDedge Hematology and Oncology
FDA approves calaspargase pegol-mknl for ALL
MDedge Hematology and Oncology
CHMP backs lusutrombopag for severe thrombocytopenia
MDedge Hematology and Oncology
CHMP recommends treosulfan for allo-HSCT conditioning
MDedge Hematology and Oncology
Long-acting interferon recommended for PV
MDedge Hematology and Oncology
CHMP backs dasatinib for kids with newly diagnosed ALL
MDedge Hematology and Oncology
Oral cancer drugs requiring prior authorization on the rise
MDedge Hematology and Oncology